Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02787616 · ClinicalTrials.gov registry record
Genetic Basis of Rosacea
A clinical trial of Rosacea, sponsored by Stanford University.
- Completed
- Registry status
- 306
- Enrollment target
- 1
- Study location
NCT02787616 is a study of Rosacea that has completed, run by Stanford University. The registered enrollment target is 306 participants, above the 230-participant average among 23 other Rosacea trials with a reported enrollment target (33% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02787616, a study of Rosacea, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 306 participants
- Enrollment target
- 1
- Study location
Study Summary
Rosacea is a common disease characterized by inflammation and vascular abnormalities of the facial skin and ocular surface. The exact pathogenesis of papulopustular rosacea is not well understood and current methods to treat this disease are often unsatisfactory. The purpose of this study is to develop gene expression profiles of papulopustular rosacea compared to those of normal skin. The investigators hope to better understand the abnormal gene functions that might contribute to this condition. This understanding may lead to the development of additional and better treatments for rosacea.
Conditions Studied
Interventions
- GENETIC buccal swab
Study Locations (1)
California
- Stanford Dermatology - Redwood City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 306 participants |
| Start Date | 2012-04-13 |
| Est. Completion | 2018-11-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02787616
The ClinicalTrials.gov registry entry for NCT02787616 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 306 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 230-participant average among 23 other Rosacea trials with a reported enrollment target (33% higher). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rosacea appearing as the primary indexed condition, and to 1 intervention - of which buccal swab is the first listed.
NCT02787616 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02787616 about?
NCT02787616 is a clinical study titled "Genetic Basis of Rosacea". Rosacea is a common disease characterized by inflammation and vascular abnormalities of the facial skin and ocular surface. The exact pathogenesis of papulopustular rosacea is not well understood and current methods to treat this disease are often unsatisfactory. The purpose of this study is to deve...
What is the current status of trial NCT02787616?
This trial is currently completed. The enrollment target is 306 participants. The study started on 2012-04-13. Estimated completion is 2018-11-16.
What conditions does trial NCT02787616 study?
This clinical trial studies the following conditions: Rosacea.
What interventions are being tested in trial NCT02787616?
The interventions under investigation include: buccal swab (GENETIC).
Who is sponsoring clinical trial NCT02787616?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02787616 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
-
Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
RECRUITING · Phase 2
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
-
Analysis of the Microbiome in Rosacea
ACTIVE NOT RECRUITING · Early Phase 1
-
Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea
COMPLETED · Phase 3
-
Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.